跳至主要内容

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

 On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs.

Medicilon and Binhui Biopharmaceutical have reached a strategic collaboration to jointly draw a new blueprint for the development of new biological drugs.webp

Gather and Work Together to Create Advantages
     Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs

As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies, ADCsmRNA vaccinessmall nucleic acid drugsPROTAC, and CGT technical service platform that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation for establishing deeper and broader collaborative relationships with global partners.

Binhui Bio has the only fully closed-loop industry-university-research integrated research platform in China for the development of oncolytic virus products - the oncolytic virus (oHSV2) immunotherapy platform.  It collaborates with multiple technology platforms of nucleic acid drugs and protein drugs to develop new Class I biological drugs, and become a pioneer in the collaborative exploration of multi-platform technologies for tumor immunotherapy.  The company's core oncolytic virus product BS001 (OH2 injection) has received NMPA and FDA approval for a total of 5 clinical approvals as a single drug and combination drug, becoming the first in the world to enter clinical research using type Ⅱ herpes simplex virus as a vector and obtain positive efficacy data of oncolytic viruses.  It is also the first major national new drug creation project for oncolytic viruses to enter confirmatory phase III clinical research.

This powerful alliance between the two parties benefits from Medicilon's drug research and development service capabilities accumulated over the years, as well as Binhui Bio's successful experience in the field of new biological drug research and development.  Based on the common vision and goals, both parties will give full play to their respective advantages in technology R&D and market expansion to achieve complementary advantages, effectively utilize resources, expand the market business scale of both parties, and create a professional contract R&D service platform.  Both parties jointly promote the research, development and application of cutting-edge technologies such as oncolytic viruses, nucleic acid drugs and protein drugs.

评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential toxicity of the compou

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

Enzyme Activity Assay Service

  Enzymatic assay Lance Assay Alphascreen Assay Z’-LYTE Assay Adapta Assay Kinase-Glo Assay ADP-Glo Assay Ligand Binding Assay ELISA Assay HTRF Assay Enzyme activity assays  are laboratory methods for measuring enzymatic activity. They are vital for the study of enzyme kinetics and enzyme inhibition. Enzyme units : Amounts of enzymes can either be expressed as molar amounts, as with any other chemical, or measured in terms of activity, in enzyme units. Medicilon provides various  enzyme activity assays  for  kinases , phosphatases, proteinases, deacetylase, peptidase, esterase, and other enzymes. Our line of well-characterized immunoassays and biochemical kits ensures accurate and reproducible results. Enzyme is a  large category of bio-molecules  that catalyze various biological processes including metabolic processes, cellular signaling and regulation, cell division and apoptosis. Enzymatic reactions convert substrate molecules into chemically modified molecules products with high sp